Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12074247 | 0.96 | CA12 (0.65) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL28512547 | 0.93 | CA12 (0.54) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL17944843 | 0.90 | CA12 (0.55) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL21131910 | 0.88 | CA12 (0.54) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL30439957 | 0.88 | TGFBR1 (0.60) | KDM4EMAPTACVR1TGFBR1MAPK14 | |
| SCHEMBL35327 | 0.88 | TGFBR1 (0.60) | KDM4EMAPTACVR1TGFBR1MAPK14 | |
| SCHEMBL17343987 | 0.87 | PIK3CA (0.56) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL21131947 | 0.87 | CA12 (0.52) | CA12CA1CA2CA9ACVR1 | |
| SCHEMBL9669763 | 0.86 | CA12 (0.58) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL21131883 | 0.86 | CA12 (0.51) | CA12CA1CA2CA9ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273948-A1 | ORGANIC LIGHT EMITTING DIODE AND DEVICE COMPRISING THE SAME | Novaled GmbH (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230292595-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230292595-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230270004-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230270004-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| EP-4199125-A1 | ORGANIC LIGHT EMITTING DIODE, METHOD FOR PREPARING THE SAME AND DEVICE COMPRISING THE SAME | Novaled GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| CN-101068551-A | Quinoline tachykinin receptor antagonists | MERCK & CO INC (US) | 2007-11-07 | — | — | CN | disclosed |
| EP-1819342-A1 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| CN-1864445-A | Organic electroluminescence device | PIONEER CORP (JP) | 2006-11-15 | — | — | CN | disclosed |
| CN-1864444-A | Organic electroluminescent device | PIONEER CORP (JP) | 2006-11-15 | — | — | CN | disclosed |
| WO-2006060390-A1 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| CN-1260784-A | Quinoline derivatives as PDEIV and INF inhibitors | DARWIN DISCOVERY LTD (GB) | 2000-07-19 | — | — | CN | disclosed |
| US-6069151-A | Quinolines and their therapeutic use | DARWIN DISCOVERY, LTD. (GB) | 2000-05-30 | — | — | US | disclosed |
| EP-0993449-A1 | QUINOLINE DERIVATIVES AS PDE IV AND/OR TNF INHIBITORS | Darwin Discovery Limited (GB) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057936-A1 | QUINOLINE DERIVATIVES AS PDE IV AND/OR TNF INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | CA12 3120/4885CA1 1784/4885CA2 2078/4885 |
| US-11691952-B2 | Nitrogen-containing compound, and electronic element and electronic device using same | NOD1, NFE2L2, NOTCH1 | CA12 3368/4885CA1 2680/4885CA2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.